Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.77 |
| ▸ | ITGA5 | P08648 | 19/20 | 0.77 |
| ▸ | ITGB3 | P05106 | 16/20 | 0.77 |
| ▸ | ITGAV | P06756 | 16/20 | 0.77 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931046 | 0.93 | ITGB1 (0.83) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL4066315 | 0.88 | ITGB1 (0.90) | ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL4203355 | 0.88 | ITGB1 (0.75) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL4068227 | 0.88 | ITGB1 (0.63) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL4919774 | 0.87 | ITGB1 (0.75) | ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL4929913 | 0.87 | ITGAV (0.76) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL14270751 | 0.86 | ITGB3 (0.80) | ITGB1ITGA5ITGB3ITGAVITGA2B | |
| SCHEMBL4193779 | 0.86 | ITGB1 (0.70) | ITGB1ITGA5ITGB3ITGAVITGA2B | |
| SCHEMBL4201436 | 0.86 | ITGB1 (0.87) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL4929607 | 0.85 | ITGB1 (0.75) | ITGB1ITGA5ITGB3ITGAVITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | claimed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | ITGB1 2/4885ITGA5 7/4885ITGB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.